VPC
TYRA icon

Vestal Point Capital’s Tyra Biosciences TYRA Stock Holding History

Vestal Point Capital’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07M Sell
54,000
-2,371,000
-98% -$76.8M 0.06% 85
2025
Q4 		$63.8M Hold
2,425,000
– – 2.17% 14
2025
Q3 		$33.9M Sell
2,425,000
-230,000
-9% -$2.62M 1.53% 24
2025
Q2 		$25.4M Sell
2,655,000
-224,829
-8% -$2.14M 1.34% 25
2025
Q1 		$26.8M Buy
2,879,829
+1,889,829
+191% +$24.5M 1.91% 18
2024
Q4 		$13.8M Buy
+990,000
New +$18M 0.82% 38

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vestal Point Capital's TYRA Position: Q1 2026 in Review

Vestal Point Capital reduced its Tyra Biosciences (TYRA) stake by 98% in Q1 2026, selling an estimated $76.8M and leaving 54,000 shares worth $2.07M. The position accounts for 0.06% of the portfolio, ranked #85.

Vestal Point Capital first reported a position in TYRA in Q4 2024 and has held it in 6 quarters since. The position peaked at $63.8M in Q4 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Vestal Point Capital held 54,000 shares of Tyra Biosciences worth $2.07M as of Q1 2026.
  • Vestal Point Capital sold 2,371,000 Tyra Biosciences shares in Q1 2026, an estimated $76.8M.
  • Tyra Biosciences made up 0.06% of Vestal Point Capital's portfolio in Q1 2026, its #85 holding.
  • Vestal Point Capital first reported a position in Tyra Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Vestal Point Capital's Tyra Biosciences position peaked at $63.8M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.